GlassScriptPhysician profile
Deval Mohan Paranjpe
NPI 1265401558
$120,935.19
in general payments reported to CMS, 2019-2025
20 companies · $26K in 2025
The $26K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $52.17 · 2021: $109 · 2022: $6,058 · 2023: $48K · 2024: $41K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Travel and Lodging: $24K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $18K · Food and Beverage: $3,140 · Consulting Fee: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $68,240.00 |
| Travel and Lodging | $23,656.28 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $18,000.00 |
| Food and Beverage | $3,140.47 |
| Consulting Fee | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $115,392.41 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $2,032.52 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $1,880.83 | 2022-2023 | Tepezza |
| Bausch & Lomb Americas INC. | $380.68 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Novartis Pharmaceuticals Corporation | $234.44 | 2019-2023 | |
| Amgen INC. | $221.08 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $137.22 | 2019-2025 | |
| Allergan, INC. | $120.04 | 2019-2021 | |
| Oyster Point Pharma, INC. | $84.22 | 2022-2025 | Tyrvaya, Ryzumvi |
| Kala Pharmaceuticals, INC. | $77.44 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $72.20 | 2024-2025 | Purified Cortrophin Gel |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $61.50 | 2023 | Lifevest |
| Dompe US, INC. | $56.38 | 2025 | Oxervate |
| Shire North American Group INC | $44.53 | 2019 | |
| Genentech USA, INC. | $34.66 | 2025 | Vabysmo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $28.35 | 2025 | Rocklatan |
| Harrow Eye, LLC | $24.10 | 2024 | Vevye |
| Regeneron Healthcare Solutions, INC. | $20.79 | 2019 | |
| Ivantis, INC | $18.70 | 2020 | |
| Eyevance Pharmaceuticals LLC | $13.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deval Paranjpe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.